| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We have established 8 kinds of hormonal therapy resistant cell lines from ER-positive breast cancer cells which were stably introduced ERE-GFP reporter plasmid. The analysis of these cell lines revealed individual molecular mechanisms of hormonal therapy resistance. Then, we analyzed cancer stemness property of these resistant cell lines (AI-resistant and fulvestrant resistant cell lines) in terms of sphere formation, side population, CD44/CD24 expression etc. The resistant cell lines which have high ER expression showed high cancer stemness property, but cell lines which lost ER expression indicated low cancer stemness marker expression. These findings will provide useful information to develop new therapeutic strategy for metastatic breast cancer.
|
